Log in

2637 Fujian Haixi Pharmaceuticals Co., Ltd. HKEX · China

Fujian Haixi Pharmaceuticals Co. (2637) news

Fujian Haixi Pharmaceuticals Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2637, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Fujian Haixi Pharmaceuticals Co. news

We have not published a story on Fujian Haixi Pharmaceuticals Co. yet. When there is news, it will appear here.

Questions about Fujian Haixi Pharmaceuticals Co.

What is the ticker symbol of Fujian Haixi Pharmaceuticals Co.?

Fujian Haixi Pharmaceuticals Co., Ltd. trades under the ticker 2637 on HKEX.

Where is Fujian Haixi Pharmaceuticals Co. listed?

Fujian Haixi Pharmaceuticals Co., Ltd. is listed on HKEX.

Which country or territory is Fujian Haixi Pharmaceuticals Co. listed under?

Our directory records Fujian Haixi Pharmaceuticals Co., Ltd. under China.

What does Fujian Haixi Pharmaceuticals Co. do?

Our directory classifies Fujian Haixi Pharmaceuticals Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Fujian Haixi Pharmaceuticals Co.?

The ISIN recorded for Fujian Haixi Pharmaceuticals Co., Ltd. is CNE100007515.

Does aibio.space cover Fujian Haixi Pharmaceuticals Co.?

aibio.space lists Fujian Haixi Pharmaceuticals Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Fujian Haixi Pharmaceuticals Co.?

Companies in our directory listed in the same country and business area as Fujian Haixi Pharmaceuticals Co.: CanSino Biologics, Stem Cell Authority, Nanjing Vazyme Biotech Co., Zhejiang Hengtong Holding Co., Shanghai Serum Bio-Technology Co., Boji Medical Technology Co..

Investor discussion: Fujian Haixi Pharmaceuticals Co.

Members talk about Fujian Haixi Pharmaceuticals Co. (2637). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Fujian Haixi Pharmaceuticals Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: 2025 AGM Circular. Source

  2. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTIONS OF FINANCIAL PRODUCTS. Source

  3. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Fujian Haixi Pharmaceuticals Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON PURCHASES OF H SHARES PURSUANT TO THE SHARE INCENTIVE SCHEME

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HX9428 LATEST DATA FROM PHASE I AND PHASE II CLINICAL STUDIES FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (nAMD)

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HX9428 SUCCESSFULLY COMPLETES PHASE I CLINICAL STUDY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND SUBMITS PHASE IIA IND APPLICATION FOR NEW INDICATION OF DIABETIC MACULAR EDEMA

  4. HKEXnews

    ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HX9428 FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION GRANTED FAST TRACK DESIGNATION (FTD) BY THE U.S. FDA

  6. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROPOSED CHANGE OF EXTERNAL AUDITOR

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF HX9428 FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION APPROVED BY THE U.S. FDA TO COMMENCE PHASE II CLINICAL TRIAL; AND INITIATION OF THE SECOND POSITIVE-CONTROLLED PHASE II CLINICAL TRIAL IN CHINA

  8. HKEXnews

    POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 4 AUGUST 2026, CHANGE OF EXTERNAL AUDITOR AND APPOINTMENT OF EXECUTIVE DIRECTOR

  9. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

  10. HKEXnews

    NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

  11. HKEXnews

    Terms of Reference of the Nomination Committee of the Board of Directors of the Company

  12. HKEXnews

    RESIGNATION OF NON-EXECUTIVE DIRECTOR AND PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

  13. HKEXnews

    PREPARATION OF FINANCIAL REPORTS IN ACCORDANCE WITH CASBE AND PROPOSED CHANGE OF AUDITOR

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - HXP089 INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR THE TREATMENT OF GLIOBLASTOMA APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT - LAUNCH OF PHASE III OSTEOSARCOMA CLINICAL TRIAL FOR C019199 TABLETS BY HAIXI PHARMACEUTICALS

  16. HKEXnews

    Rules of Procedure for Meeting of the Board of Directors

  17. HKEXnews

    Rules of Procedure for Shareholders' Meeting

  18. HKEXnews

    Articles of Association

  19. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 MAY 2026, CHANGE OF DIRECTORS, ELECTION OF CHAIRMAN AND APPOINTMENT OF SENIOR MANAGEMENT, CHANGE IN COMPOSITION OF BOARD COMMITTEE AND ABOLISHMENT OF THE BOARD OF SUPERVISORS

  20. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2637 on TradingView.

Listing details

Fujian Haixi Pharmaceuticals Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2637, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Fujian Haixi Pharmaceuticals Co., Ltd.
Ticker
2637
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007515
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.